Douglas J. Swirsky, has served as the President and Chief Executive Officer and as a director of the Company since September 2013. He joined GenVec in 2006 as Chief Financial Officer, Corporate Secretary and Treasurer; and continues to serve as Corporate Secretary. Prior to joining the Company, Mr. Swirsky was a Managing Director and the Head of Life Sciences Investment Banking at Stifel Nicolaus from 2005 to 2006 and held investment banking positions at Legg Mason from 2002 until Stifel Financial's acquisition of the Legg Mason Capital Markets business in 2005. Mr. Swirsky, a Certified Public Accountant and CFA® charterholder, previously held investment banking positions at UBS, PaineWebber, and Morgan Stanley. His experience also includes positions in public accounting and consulting. Mr. Swirsky received his undergraduate degree in Business Administration from Boston University and his M.B.A. from the Kellogg School of Management at Northwestern University. Mr. Swirsky is Chairman of the Board of Directors of Fibrocell Science, Inc.
Doug Brough joined GenVec in 1993 and serves as Chief Scientific Officer, having previously held senior positions in GenVec Research. Dr. Brough was directly involved in the discovery and development of GenVec’s AdenoVerse™ technology platform, which includes adenovirus vectors of human and non-human origins and proprietary production cell lines with demonstrated scale-up and production viability. He leads GenVec’s hearing and balance program, which resulted in the CGF166 therapeutic drug candidate for hearing loss, currently in clinical testing and being developed by Novartis under the terms of a worldwide licensing and collaboration agreement. Dr. Brough also led the research efforts which resulted in the first adenovector-based Foot and Mouth Disease vaccine to be approved by the USDA as part of a collaboration between GenVec, the Agricultural Research Service of the USDA, and the Department of Homeland Security. Dr. Brough received his B.S. in Biology from Purdue University; his M.S. in Microbiology and Biochemistry from Idaho State University, and his Ph.D. in Microbiology and Molecular Genetics from Rutgers, the State University of New Jersey and the Robert Wood Johnson Medical School; and performed post-doctoral research in molecular biology at Princeton University.
Bryan T. Butman, Ph.D. joined the company in 1999 and now serves as Senior Vice President, Development. Dr. Butman previously served as GenVec's Vice President of Vector Operations (2005 to 2006), Vice President of Quality (2002 to 2005), and Director of Quality and Analytical Science (1999 to 2002). Prior to joining GenVec, Dr. Butman was Executive Director of Diagnostic Product Research and Development with INTRACEL Corporation, a biotechnology company. Dr. Butman has over 30 years of biotechnology product development experience including clinical gene therapy, human monoclonal antibody and clinical diagnostic products. Throughout his biotechnology career, Dr. Butman has developed successful products in the areas of oncology, cardiovascular disease, infectious disease, food safety and hematology. He has held senior positions within Warner Lambert, AKZO-Nobel, Organon Teknika, PerImmune and INTRACEL. Dr. Butman holds a Ph.D. in Cell Biology from Wayne State University.